Hypercholesterolemia

Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Mon, 26 Dec 2022 14:24:58 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Drugs In Development, 2022, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under de...

$2,000.00

Heterozygous familial hypercholesterolemia (heFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Mon, 26 Dec 2022 14:24:58 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis...

$2,000.00

Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data...

$2,000.00

Heterozygous Familial Hypercholesterolemia (heFH) - Global Clinical Trials Review, H2, 2021

Fri, 03 Sep 2021 16:07:52 +0000

Summary

GlobalData's clinical trial report, “Heterozygous familial hypercholesterolemia (heFH) - Global Clinical Trials Review, H2, 2021" provides an overview of Heterozygous familial hypercholesterolemia (heFH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Heterozygous familial hypercholesterolemia (heFH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the d...

$2,500.00

Familial Hypercholesterolemia – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “Familial Hypercholesterolemia – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Familial Hypercholesterolemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Familial Hypercholesterolemia Understanding Familial Hypercholesterolemia: Overview Familial hypercholesterolemia is an inherited condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. In people with familial hypercholesterolemia, the body is unab...

$1,500.00

Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2018

Thu, 29 Nov 2018 15:00:25 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia - Pipeline Review, H2 2018, provides an overview of the Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Homozygous Familial Hypercholesterolemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmaco...

$2,000.00

Hypercholesterolemia - Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

Note*: This report requires 5-10 business days to complete. DelveInsight’s Hypercholesterolemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Hypercholesterolemia forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Hypercholesterolemia till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Hypercholesterolemia market. • Identifying patient populations in the global “Hypercholesterolemiamarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Hypercholesterolemia therapeutics in each of the ...

$4,950.00

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016

Fri, 09 Dec 2016 10:18:51 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis by ...

$2,000.00

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016

Fri, 16 Sep 2016 20:41:29 +0000

Summary

GlobalData's clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016" provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic proce...

$2,500.00